EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Suppressor of TCR signaling 2 (Sts-2) as a potential immunotherapy target and prognostic biomarker in cervical cancer

Yinlong Chen iD, Qin Chen iD, Xiaoqing Guo iD, Qingliang Zheng iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Yinlong Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Prenatal Diagnosis Center, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, P.R. China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Biomarkers, Tumor, Carcinoma, Squamous Cell, Adenocarcinoma. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NNSFC, Natural Science Foundation of Guangdong, Shenzhen Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: More efficient immune targets are needed for the treatment of cervical cancer. This study aimed to identify potential targets for immunotherapy and prediction in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) by conducting bioinformatics analysis and verifying the results with clinical tissue samples. METHODS: A retrospective analysis of RNA sequencing data from 304 patients sourced from The Cancer Genome Atlas (TCGA) and another 300 patients from the Gene Expression Omnibus (GEO) was performed to investigate the correlation between suppressor of TCR signaling 2 (Sts-2) expression and clinical parameters in cervical cancer. To authenticate our findings, we utilized a combination of immunohistochemistry, quantitative polymerase chain reaction, and western blotting techniques in a separate cohort consisting of 6 cervical cancer tissue samples. RESULTS: The Sts-2 gene was discovered to be substantially co-expressed with a multitude of immune checkpoint molecules, including programmed cell death protein 1 (r=0.8, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsBiomarkers, TumorCarcinoma, Squamous CellAdenocarcinomaHumansFemalePrognosisRetrospective StudiesImmunotherapyMiddle AgedAdultAged

Stichwörter der Autor:innen

Cervical CancerImmunotherapyPrognosis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Prenatal Diagnosis Center, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, P.R. China.
  • Department of Gynecological Oncology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, PR China. guoxiaoqing@51mch.com.
  • Prenatal Diagnosis Center, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, P.R. China. zhengqliang@mail.sysu.edu.cn.

ORCID-Profile: Yinlong Chen, Qin Chen, Xiaoqing Guo, Qingliang Zheng

Förderung

  • NNSFC
  • Natural Science Foundation of Guangdong
  • Shenzhen Science and Technology Program
  • Futian Healthcare Research Project
  • National Natural Science Foundation of China

Zitieren

APA

Chen, Y., Chen, Q., Guo, X., & Zheng, Q. (2026). Suppressor of TCR signaling 2 (Sts-2) as a potential immunotherapy target and prognostic biomarker in cervical cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e20

Vancouver

Chen Y, Chen Q, Guo X, Zheng Q. Suppressor of TCR signaling 2 (Sts-2) as a potential immunotherapy target and prognostic biomarker in cervical cancer. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e20

BibTeX
@article{Chen2026,
  author = {Chen, Yinlong and Chen, Qin and Guo, Xiaoqing and Zheng, Qingliang},
  title = {Suppressor of TCR signaling 2 (Sts-2) as a potential immunotherapy target and prognostic biomarker in cervical cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e20}
}
Kostenlos starten →